Literature DB >> 8056344

Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III.

F Agnès1, B Shamoon, C Dina, O Rosnet, D Birnbaum, F Galibert.   

Abstract

The FLT3 gene encodes a subclass-III receptor tyrosine kinase (RTKIII). We have determined the structural organization of the downstream part of the human FLT3 gene (also designated dsp-FLT3) that corresponds to the intracellular region of the protein. The coding region is spread over twelve exons spanning 10 kb of genomic DNA. Exon sizes range from 83 to 154 bp, while intron sizes range from 86 bp to more than 1.9 kb. Comparison with the corresponding domain of other RTKIII genes (KIT and FMS) shows that these genes share the same number of exons, which are highly conserved in size, sequence and exon/intron boundary positions. In addition, the intron phase of equivalent introns of FLT3, KIT and FMS are all identical. Our results reinforce our hypothesis based initially only on the KIT and FMS comparison showing that RTKIII genes share a common structural organization and have evolved from a common ancestor gene by cis and trans duplication. Comparison of the genomic organization of the intracellular-encoding part of RTKIII genes with that of RTKI, II and IV genes shows that subclasses III and IV are the most closely related.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056344     DOI: 10.1016/0378-1119(94)90021-3

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  11 in total

1.  Genomic organization of the extracellular coding region of the human FGFR4 and FLT4 genes: evolution of the genes encoding receptor tyrosine kinases with immunoglobulin-like domains.

Authors:  F Agnès; M M Toux; C André; F Galibert
Journal:  J Mol Evol       Date:  1997-07       Impact factor: 2.395

2.  Treatment of FLT3-ITD acute myeloid leukemia.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Am J Blood Res       Date:  2011-09-09

3.  FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

Authors:  Amir T Fathi; Bruce A Chabner
Journal:  Oncologist       Date:  2011-07-17

4.  Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains.

Authors:  D Rousset; F Agnès; P Lachaume; C André; F Galibert
Journal:  J Mol Evol       Date:  1995-10       Impact factor: 2.395

Review 5.  Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

Authors:  Yun Chen; Yihang Pan; Yao Guo; Wanke Zhao; Wanting Tina Ho; Jianlong Wang; Mingjiang Xu; Feng-Chun Yang; Zhizhuang Joe Zhao
Journal:  Stem Cell Investig       Date:  2017-06-02

Review 6.  FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

Authors:  Baku Acharya; Debasmita Saha; Daniel Armstrong; Naga Rajiv Lakkaniga; Brendan Frett
Journal:  RSC Med Chem       Date:  2022-05-23

7.  Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.

Authors:  Yesid Alvarado; Hagop M Kantarjian; Rajyalakshmi Luthra; Farhad Ravandi; Gautam Borthakur; Guillermo Garcia-Manero; Marina Konopleva; Zeev Estrov; Michael Andreeff; Jorge E Cortes
Journal:  Cancer       Date:  2014-04-15       Impact factor: 6.860

8.  Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype.

Authors:  Dawn Sijin Nin; Wai Kay Kok; Feng Li; Shinichiro Takahashi; Wee Joo Chng; Matiullah Khan
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

Review 9.  An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.

Authors:  Tiziana Grafone; Michela Palmisano; Chiara Nicci; Sergio Storti
Journal:  Oncol Rev       Date:  2012-04-17

Review 10.  Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.

Authors:  Melat T Gebru; Hong-Gang Wang
Journal:  J Hematol Oncol       Date:  2020-11-19       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.